First Tracks Biotherapeutics Stock Surges 13% on Positive Celiac Trial Results

Key Facts

1First Tracks Biotherapeutics stock surged 13% on Monday following positive Phase 1b trial results.

2The positive results pertain to the Phase 1b trials of the drug ANB033 for celiac disease.

First Tracks Biotherapeutics stock surged 13% on Monday. Benzinga reported that the price action followed the company's announcement of positive Phase 1b clinical trial results for ANB033, a drug candidate designed to treat celiac disease.

TRAX closed at $31.85 on October 9, 2026, after reaching a day high of $33.28 and a low of $30.72. The positive clinical data pertained to the efficacy and safety of the drug during the study.